Journal of Clinical Lipidology
Volume 6, Issue 1 , Pages 19-26 , January 2012

Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity

  • Rebecca L. Attridge, PharmD, MSc

      Affiliations

    • University of the Incarnate Word, 4301 Broadway CPO#99, San Antonio, TX 78209, USA
    • University of Texas at Austin, Austin, TX, USA
    • University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • William D. Linn, PharmD

      Affiliations

    • University of the Incarnate Word, 4301 Broadway CPO#99, San Antonio, TX 78209, USA
    • University of Texas at Austin, Austin, TX, USA
    • ,
  • Laurajo Ryan, PharmD, MSc

      Affiliations

    • University of Texas at Austin, Austin, TX, USA
    • University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    • ,
  • Jim Koeller, MSc

      Affiliations

    • University of Texas at Austin, Austin, TX, USA
    • University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    • ,
  • Christopher R. Frei, PharmD, MSc

      Affiliations

    • University of Texas at Austin, Austin, TX, USA
    • University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

Received 20 May 2011 ,Accepted 30 August 2011.

  • Image Result

    Patient inclusion and exclusion flow sheet.

    Patient inclusion and exclusion flow sheet.

  • Image Result

    Incidence of fenofibrate-associated nephrotoxicity. Any renal disease includes patients with CKD (n = 29), obstructive nephropathy (n = 1), IgA nephropathy (n = 1), renal cancer (n = 1), nephrolithias

    Incidence of fenofibrate-associated nephrotoxicity. Any renal disease includes patients with CKD (n = 29), obstructive nephropathy (n = 1), IgA nephropathy (n = 1), renal cancer (n = 1), nephrolithiasis (n = 1), membranous glomerulonephritis (n = 2), previous nephrectomy (n = 2), and focal segmental glomerulosclerosis (n = 2). ∗P < .05 for all comparisons.

  • Image Result
    Temporal relationship between initiation of fenofibrate and ≥0.3 mg/dL elevation in SCr.

    Temporal relationship between initiation of fenofibrate and ≥0.3 mg/dL elevation in SCr.

PII: S1933-2874(11)00708-2

doi: 10.1016/j.jacl.2011.08.008

Journal of Clinical Lipidology
Volume 6, Issue 1 , Pages 19-26 , January 2012

Article Tools

* Image Usage & Resolution